UBS AM’s Inhibrx, Inc. Common Stock INBX Stock Holding History

UBS AM’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-29,580	Closed	-$1.03M	–	2912
2024 Q1	$1.03M	Sell	29,580 -2,637	-8%	-$96.2K	﹤0.01%	1997
2023 Q4	$1.22M	Hold	32,217	–	–	﹤0.01%	1921
2023 Q3	$591K	Buy	+32,217	New	+$674K	﹤0.01%	2226
2023 Q1	–	Sell	-17,638	Closed	-$435K	–	2761
2022 Q4	$435K	Buy	+17,638	New	+$518K	﹤0.01%	2231
2022 Q3	–	Sell	-10,080	Closed	-$114K	–	2816
2022 Q2	$114K	Buy	+10,080	New	+$148K	﹤0.01%	2635

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

UBS AM's INBX Position: Q2 2024 in Review

UBS AM sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 29,580 shares — an estimated $1.03M sold.

UBS AM first reported a position in INBX in Q2 2022 and held it in 5 quarters. The position peaked at $1.22M in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

UBS AM reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
UBS AM sold 29,580 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $1.03M.
UBS AM first reported a position in Inhibrx, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
UBS AM's Inhibrx, Inc. Common Stock position peaked at $1.22M in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on UBS AM's 13F filing for Q2 2024, filed 14 Aug 2024.